Matt is the CEO of IntelliQuit, the world's first cloud-based biochemical nicotine monitor which leverages the power of smartphone technology, computer vision, neural network architecture, and machine learning.  He has been engaged in the treatment, management, and administration of nicotine addiction services for over three decades and may have treated more tobacco dependent patients than anyone else in the United States. Matt is the co-developer and clinical director of the Tobacco Treatment Program of the New York City Fire Department (FDNY) which enjoys a biochemically confirmed quit rate of approximately 70 percent at 10-year follow-up. He was also appointed the clinical director of the IQuit Smoking Program at RWJBarnabas Health-Jersey City Medical Center, Jersey City, NJ, and to their medical staff in 2011.  In March 2013, he joined the faculty of St. George’s School of Medicine, Department of Psychiatry.  Matt is a past president of the Association for the Treatment of Tobacco Use and Dependence (www.ATTUD.org ).  ATTUD is a non-profit global organization of providers dedicated to the promotion of and increased access to evidence-based tobacco treatment for the tobacco user.  Since December 2006, he has been retained by the American College of Chest Physicians as a principal author for their Tobacco Treatment Toolkit–an on-line training and consultation document for pulmonologists and other clinicians worldwide.  In 1994, Matt was retained as an expert consultant to the federal class action Castano tobacco litigation. This hallmark litigation resulted in the 300 billion-dollar, 46-State Attorneys General Master Settlement Agreement.  Matt has also been called to testify before the FDA and the Center for Medicare Medicaid Services (CMS) concerning various tobacco treatment topics.  He was an adjunct faculty member of the Addictions Certification Program of Bergen County College teaching nicotine dependence theory and clinical practice and has functioned as a consultant to various pharmaceutical, medical diagnostics, and healthcare organizations.  He also serves on the editorial boards of the Journal of Smoking Cessation and the Journal of Medical Internet Research.